




Supplemental Figure 1. Kaplan–Meier curves for overall survival of patients with high-risk stage II or III colon cancer who received adjuvant oral or intravenous fluoropyrimidine



Supplemental Figure 2. Kaplan–Meier curves for overall survival of patients with high-risk stage II colon cancer who received adjuvant oral or intravenous fluoropyrimidine



Supplemental Figure 3. Kaplan–Meier curves for overall survival of patients with stage III colon cancer who received adjuvant oral or intravenous fluoropyrimidine



Supplemental Table 1. Characteristics of adjuvant oral or intravenous fluoropyrimidine chemotherapy for patients with colon adenocarcinoma who received curative surgery and their nonmatched cohort

	Oral Fluoropyrimidine N = 2,468	IV Fluoropyrimidine N = 2,468	SMD
Adjuvant chemotherapy duration (days), median (IQR)	286.5 (271.0)	201.0 (59.0)	-
Follow-up time (years)			
Mean (SD)	6.4 (3.4)	8.3 (3.7)	0.5623
Median (IQR)	5.8 (5.3)	8.1 (6.5)	-
Total cycles of chemotherapy			
Mean (SD)	5.4 (3.8)	4.8 (4.2)	0.3261
Median (IQR)	5.0 (3.0)	4.0 (4.0)	-
Total cumulative dose of chemotherapy (mg/m²)			
Mean (SD)	109 411.5 (96 058.4)	5524.5 (2704.2)	1.5971
Median (IQR)	81 200.0 (95 200.0)	5700.0 (2800.0)	-

SMD, standardized mean difference; SD, standard deviation; IQR, interquartile range; IV, intravenous